Haichuang Pharmaceutical (688302)
Promising international innovative pharmaceutical enterprises
Haichuang Pharmaceutical Co., Ltd. is an international innovative drug enterprise based on deuterated technology and protac targeted protein degradation technology platform, aiming at developing best in class and first in class drugs with major clinical needs. The company focuses on the research and development of innovative drugs in major treatment fields such as tumors and metabolic diseases. At present, the main indications of products under research are "prostate cancer" and "gout", which are in clinical phase 3 and phase 2 respectively.
According to frost Sullivan's data, as of 2019, there were 32 million ventilation patients in China, and the number of gout is expected to increase in the future, reaching 43.3 million and 56.2 million in 2024 and 2035 respectively. The market scale of prostate cancer AR inhibitors in China has increased from 500 million yuan in 2015 to 900 million yuan in 2019, and it is expected that by 2024, its market scale will reach 7.2 billion yuan, By 2030, China's prostate cancer ar inhibitor market will further grow to 23.9 billion yuan. In addition, the company's products under research are conducting clinical trials in China and overseas at the same time. It is expected that both products will be NDA in 2023. It can be seen that the market prospect is excellent.
Clear ownership structure, favored by capital
As the largest shareholder of the company, Chen Yuanwei holds 27.42% through affinitisco, hinovallc and Haichuang Tongli, and his brother Chen Yuanlun holds 5.16%. Yingchuang power owns 14.23% of the shares of the company, and the actual controller is song Jiajun Haisco Pharmaceutical Group Co.Ltd(002653) and amhiron own 4.38% and 2.11% respectively, and the remaining 46.72% of the shares are held by 53 other shareholders.
